influenza
viru
infect
remain
seriou
threat
global
health
world
economi
annual
influenza
epidem
result
larg
number
hospit
estim
million
case
sever
diseas
approxim
death
global
http
wwwwhointmediacentrefactsheet
much
higher
mortal
rate
possibl
pandem
despit
substanti
innov
treatment
prevent
influenza
licens
antivir
drug
vaccin
elimin
risk
infect
prompt
treatment
therapeut
antivir
neuraminidas
na
inhibitor
lower
influenza
morbid
drug
limit
therapeut
window
subject
sporad
resist
activ
antivir
immun
prophylact
influenza
vaccin
remark
lower
season
influenza
morbid
mortal
popul
level
howev
atrisk
group
infant
elderli
otherwis
immunecompromis
individu
lack
optim
adapt
immun
respons
follow
vaccin
furthermor
counteract
high
rate
influenza
viru
antigen
drift
season
vaccin
must
reformul
readminist
annual
great
cost
signific
time
constraint
emerg
strain
influenza
aris
antigen
shift
reassort
crossspeci
transmiss
human
also
pose
consider
pandem
threat
limit
capac
develop
new
vaccin
meet
immediaci
high
demand
accompani
pandem
outbreak
highlight
global
need
new
broad
costeffect
intervent
strategi
influenza
passiv
immun
util
antibodybas
approach
notabl
altern
adjunct
therapi
transient
protect
influenza
rel
recent
sever
laboratori
describ
new
class
influenzaneutr
monoclon
antibodi
target
conserv
site
hemagglutinin
ha
antigen
crossreact
across
divers
influenza
influenza
b
virus
preclin
studi
mice
ferret
reveal
novel
crossreact
antibodi
effect
prevent
treat
sever
influenza
infect
support
studi
antibodi
immunoprophylaxi
immunotherapi
influenza
virusinfect
human
great
stride
antibodi
deliveri
made
expens
bioprocess
monoclon
antibodi
well
current
requir
frequent
administr
like
pose
limit
univers
adopt
approach
dissemin
global
popul
altern
deliveri
technolog
coopt
aspect
tradit
associ
immun
viral
vector
gene
therapi
shown
promis
deliv
antiinfluenza
antibodi
mice
perman
concern
preexist
antivector
serolog
may
limit
util
repeatedli
use
viral
vector
human
distinct
approach
antibodi
immun
therapi
would
allow
simplic
product
lower
cost
high
stabil
eas
deliver
could
advantag
regard
technolog
dnaencod
protein
antigen
deliveri
specif
advantag
demonstr
recent
success
dna
vaccin
field
plasmid
dna
welltoler
nonintegr
requir
coldchain
distribut
deliv
repeatedli
rel
inexpens
produc
howev
date
abil
produc
substanti
level
protein
express
system
vivo
deliveri
plasmid
dna
consid
feasibl
studi
describ
construct
develop
vivo
deliveri
dna
plasmid
encod
optim
influenzaspecif
broadli
neutral
antibodi
flua
flub
target
divers
influenza
influenza
b
virus
respect
deliveri
flua
dmab
flub
dmab
result
robust
vivo
express
function
antibodi
protect
mice
lethal
challeng
show
first
time
flua
flub
dmab
function
equival
correspond
protein
monoclon
antibodi
purifi
vitro
cell
product
dmab
impart
simultan
prophylact
crossprotect
divers
strain
influenza
influenza
b
viru
given
combin
furthermor
flua
dmab
flub
dmab
afford
immedi
protect
without
inhibit
host
antivir
immun
dmab
antiinfluenza
technolog
provid
uniqu
altern
strategi
season
vaccin
bioprocess
recombin
protein
monoclon
antibodi
gene
therapi
approach
univers
prevent
sever
influenza
infect
approach
import
implic
protect
treatment
infecti
diseas
flua
flub
dnaencod
monoclon
antibodi
express
vitro
vivo
broadlyneutr
monoclon
antibodi
influenza
flua
influenza
b
flub
isol
human
memori
bcell
previous
describ
flua
monoclon
antibodi
close
relat
recent
publish
broadlyneutr
monoclon
antibodi
show
wide
rang
ha
crossreact
due
bind
ha
stalk
capabl
neutral
influenza
virus
group
group
averag
ic
data
shown
flub
monoclon
antibodi
identifi
select
base
abil
potent
neutral
influenza
b
virus
belong
victoria
yamagata
lineag
averag
ic
data
shown
antibodi
bind
conserv
region
globular
head
influenza
b
ha
inhibit
viral
hemagglutin
red
blood
cell
test
util
dmab
deliveri
prevent
sever
influenza
infect
synthet
dna
transgen
encod
either
human
igg
flua
flub
synthes
de
novo
clone
mammalian
express
plasmid
multipl
modif
made
enhanc
dmab
express
includ
dna
codon
optim
rna
optim
formul
plasmid
dna
supplement
fig
well
plasmid
vector
design
incorpor
leader
sequenc
process
secret
electropor
techniqu
quantit
enzymelink
immunosorb
assay
elisa
human
igg
human
embryon
kidney
cell
transfect
either
flua
dmab
flub
dmab
synthet
construct
confirm
intracellular
express
extracellular
secret
flua
flub
antibodi
respect
fig
human
igg
western
blot
also
demonstr
antibodi
heavychain
lightchain
express
transfect
cell
fig
athym
nu
crl
nude
mice
inocul
flua
flub
dmab
plasmid
dna
via
intramuscular
inject
dose
util
intramuscular
electropor
imep
formul
hyaluronidas
enhanc
dmab
deliveri
express
supplement
figur
peak
express
level
nude
mous
sera
reach
mean
sem
sem
flua
dmab
flub
dmab
respect
notabl
signific
human
igg
express
persist
week
fig
beyond
indic
vivo
stabil
dna
plasmid
antibodi
express
next
defin
express
antiinfluenza
dmab
immunecompet
balbc
mice
fig
f
establish
influenza
challeng
model
balbc
mice
receiv
plasmid
dna
via
imep
flua
dmab
construct
gener
modest
level
human
igg
balbc
mous
sera
measur
day
post
deliveri
plasmid
mean
sem
similar
observ
nude
mice
flub
dmab
express
robust
flua
dmab
express
day
post
deliveri
mean
sem
mean
sem
unlik
stabl
express
observ
nude
mice
serum
dmab
level
balbc
mice
undetect
day
post
deliveri
like
due
mous
adapt
antihumanigg
respons
express
dmab
collect
data
clearli
demonstr
dmab
human
igg
produc
substanti
level
vivo
follow
administr
plasmid
construct
vivoexpress
influenza
dmab
function
activ
demonstr
broad
crossreact
vitro
bind
activ
sera
collect
dmabtreat
balbc
mice
determin
test
dmab
gener
vivo
retain
crossreact
multipl
subtyp
influenza
lineag
influenza
b
flua
dmab
sera
bound
comprehens
array
influenza
group
group
ha
antigen
virus
known
infect
human
tabl
includ
recombin
trimer
ha
repres
season
potenti
pandem
influenza
isol
fig
well
recombin
monomer
ha
supplement
fig
flub
dmab
murin
sera
bound
influenza
b
ha
repres
victoria
yamagata
lineag
virus
fig
halfmaxim
effect
concentr
ec
reciproc
serum
dilut
indic
higher
bind
activ
sera
mice
receiv
plasmid
dna
reflect
increas
dmab
express
level
potent
vitro
neutral
capabl
parent
flub
monoclon
antibodi
allow
neutral
activ
test
wherea
potenc
flua
monoclon
antibodi
allow
differenti
nonspecif
interfer
mous
serum
microneutr
assay
sera
mice
receiv
flub
dmab
plasmid
construct
effect
neutral
yamagata
victoria
lineag
influenza
b
virus
vitro
cellbas
assay
fig
similar
pattern
reactiv
seen
bind
assay
normal
human
igg
concentr
sampl
calcul
half
maxim
inhibitori
concentr
ic
mice
treat
flub
dmab
plasmid
b
florida
fig
direct
comparison
dmab
versu
purifi
protein
recombin
flub
monoclon
antibodi
administ
ip
separ
group
day
prior
infect
quantif
human
igg
present
mous
serum
time
challeng
show
flub
dmab
yield
similar
mean
human
igg
concentr
ha
bind
activ
observ
anim
treat
mgkg
flub
protein
ip
fig
supplement
fig
remark
flub
dmabtreat
mice
surviv
victoria
yamagata
lethal
influenza
b
challeng
wherea
nonspecif
dmab
control
fulli
succumb
infect
day
fig
e
consist
surviv
data
flub
dmab
protect
mice
influenza
brelat
morbid
treat
anim
exhibit
littletono
weight
loss
fig
f
addit
flub
dmabtreat
mice
exhibit
significantli
lower
lung
viral
load
observ
control
mice
supplement
fig
surviv
weight
loss
lung
viral
load
vitro
bind
activ
sera
flub
dmabtreat
mice
close
parallel
paramet
mice
receiv
mgkg
fig
influenza
aspecif
bspecif
elisa
show
flua
flub
dmab
exhibit
express
level
similar
observ
sera
mice
receiv
mgkg
recombin
flua
monoclon
antibodi
mgkg
recombin
flub
monoclon
antibodi
deliv
ip
respect
fig
mice
receiv
flua
plu
flub
dmab
complet
protect
lethal
infect
wherea
mice
treat
control
dmab
succumb
influenza
b
infect
respect
fig
dmab
administr
deliveri
protein
igg
result
similar
level
protect
appar
surviv
rate
bodi
weight
loss
supplement
fig
twentyon
day
follow
initi
infect
sera
surviv
balbc
mice
undetect
level
human
igg
data
shown
indic
dmab
recombin
protein
longer
present
serum
hemagglutin
inhibit
hai
mous
antiha
bind
antibodi
infect
influenza
strain
confirm
mice
mount
host
immun
respons
infect
supplement
fig
dmabtreat
mice
abl
mount
host
immun
respons
viru
extent
purifi
iggtreat
anim
twentyeight
day
follow
initi
infect
surviv
mice
includ
one
dmab
control
mous
surviv
initi
infect
rechalleng
lethal
dose
homolog
influenza
viru
confirm
level
mous
host
immun
respons
protect
previouslychalleng
mice
surviv
lethal
homolog
rechalleng
without
substanti
weight
loss
wherea
untreat
agematch
mice
infect
surviv
fig
f
supplement
fig
result
demonstr
protect
host
antiinfluenza
respons
develop
presenc
protect
level
flua
flub
antibodi
whether
express
vivo
dmab
deliv
protein
monoclon
antibodi
demonstr
dmab
antagon
host
immun
respons
influenza
season
influenza
infect
result
annual
averag
billion
usd
direct
medic
cost
billion
usd
econom
burden
unit
state
alon
despit
avail
influenza
vaccin
antivir
drug
larg
subpopul
remain
suscept
complic
aris
season
influenza
infect
almost
death
attribut
season
influenza
unit
state
occur
adult
year
older
popul
estim
vaccin
efficaci
low
year
signific
antigen
drift
http
wwwcdcgovflu
professionalsvaccinationeffectivenessqahtm
standard
vaccin
technolog
addit
persist
hazard
season
infect
pandem
influenza
outbreak
threaten
outpac
vaccin
design
therefor
innov
univers
intervent
influenza
infect
vital
current
effort
creat
univers
influenza
vaccin
focus
design
recombin
antigen
serv
immunogen
spur
activ
immun
matur
host
crossprotect
antiinfluenza
antibodi
concord
discoveri
novel
broadlyneutr
antiinfluenza
monoclon
antibodi
suggest
passiv
immun
may
complement
bypass
tradit
immun
strategi
influenza
sought
bypass
activ
immun
gener
crossprotect
antibodi
respons
via
inocul
dmab
show
approach
gener
function
antiinfluenza
antibodi
mous
sera
follow
inocul
plasmid
dna
construct
encod
two
antibodi
ha
influenza
subtyp
known
caus
diseas
human
lead
signific
protect
lethal
season
influenza
influenza
b
challeng
studi
underway
enhanc
dmab
express
assess
vivo
capabl
dmab
protect
highli
pathogen
avian
influenza
virus
potenti
pandem
strain
plethora
protein
monoclon
antibodi
commerci
avail
treatment
autoimmun
diseas
cancer
chronic
condit
yet
given
expens
administ
biolog
limit
halflif
one
protein
monoclon
antibodi
approv
routin
use
prophylaxi
infecti
diseas
target
palivizumab
rsv
dmab
technolog
notabl
deliveri
altern
dmab
produc
muscl
cell
vivo
purifi
monoclon
antibodi
manufactur
vitro
confer
similar
level
protect
lethal
influenza
infect
mice
plasmid
dna
lack
limit
pose
preexist
antivector
serolog
dmab
platform
may
util
repeatedli
deliv
addit
antiinfluenza
antibodi
combat
viral
escap
antibodi
aim
entir
differ
pathogen
plasmid
dna
also
littl
risk
genom
integr
review
ref
similar
plasmid
design
demonstr
safeti
dna
vaccin
human
clinic
studi
dna
plasmidbas
deliveri
monoclon
antibodi
provid
conceptu
advantag
step
suppli
chain
product
dmab
inexpens
rel
protein
monoclon
antibodi
viral
vector
dna
replic
requir
mammalian
cell
cultur
dna
simpl
scale
stabl
storag
particularli
import
consider
resourcelimit
set
potenti
longterm
dmab
express
sustain
passiv
immun
protect
influenza
infect
may
circumv
need
frequent
recombin
antibodi
inject
longterm
express
dmab
augment
emerg
antibodi
halflif
extens
technolog
conceiv
inocul
influenzaspecif
dmab
may
util
augment
vaccin
campaign
gener
almost
immedi
prophylaxi
sever
influenza
infect
allow
adequ
vaccineinduc
immun
respons
matur
dmab
may
also
provid
vital
option
sever
immun
impair
individu
incap
mount
function
activ
immun
respons
dmab
technolog
except
compel
tool
warrant
explor
sustain
protect
sever
infect
divers
strain
influenza
b
virus
well
investig
infecti
diseas
gener
monoclon
antibodi
isol
use
similar
methodolog
describ
previous
influenza
monoclon
antibodi
flua
isol
base
crossreact
bind
ha
protein
influenza
b
monoclon
antibodi
flub
isol
base
neutral
activ
distinct
lineag
influenza
b
variabl
gene
sequenc
isol
crossreact
clone
revers
transcript
polymeras
chain
reaction
clone
modifi
revert
nonessenti
nongermlin
framework
amino
acid
chang
fulllength
human
transient
express
cho
cell
purifi
use
vivo
studi
plasmid
dmab
construct
engin
previous
describ
dmab
construct
encod
fulli
human
monoclon
antibodi
flua
dmab
flub
dmab
antibodi
amino
acid
sequenc
dna
codonoptim
rnaoptim
express
human
mous
result
dna
transgen
synthes
de
novo
genscript
piscataway
nj
usa
synthet
transgen
restrictionclon
modifi
mammalian
express
vector
invitrogen
cytomegaloviru
immediateearli
promot
ige
heavychain
lightchain
leader
sequenc
ad
cellular
process
secret
initi
studi
fig
transgen
consist
antibodi
heavychain
lightchain
sequenc
separ
furin
peptid
cleavag
site
sequenc
yield
express
heavychain
lightchain
peptid
singl
plasmid
later
studi
coadministr
flua
flub
dmab
fig
two
flua
dmab
construct
individu
express
heavychain
lightchain
flua
peptid
mix
express
heavychain
lightchain
flua
peptid
separ
plasmid
human
cell
atcc
maintain
dulbeco
modifi
eagl
medium
invitrogen
supplement
fetal
bovin
serum
fb
one
day
prior
transfect
cell
plate
cell
per
well
plate
transfect
plasmid
dna
use
genejamm
agil
technolog
h
later
supernat
collect
adher
cell
lyse
cell
lysi
buffer
cell
signal
proteas
inhibitor
cocktail
roch
boehring
mannheim
approxim
total
supernatantlys
protein
protein
igg
run
seeblu
prestain
protein
standard
thermo
fisher
scientif
precast
bistri
gel
invitrogen
transfer
immobilonfl
pvdf
membran
emd
millipor
use
iblot
dri
blot
system
thermo
fisher
scientif
heavychain
lightchain
peptid
identifi
use
irdy
goat
antihuman
igg
h
l
licor
bioscienc
fluoresc
blot
scan
odyssey
clx
licor
bioscienc
quantit
elisa
quantif
total
human
cell
lysat
cell
supernat
mous
sera
fig
supplement
fig
maxisorp
plate
nunc
coat
overnight
goat
antihuman
igg
f
c
fragment
bethyl
laboratori
plate
block
fb
phosphatebuff
salin
pb
sampl
dilut
pb
tween
ad
plate
h
standard
curv
gener
use
purifi
human
bethyl
laboratori
plate
stain
hrpconjug
secondari
antibodi
goat
antihuman
kappa
lightchain
bethyl
laboratori
h
develop
use
sigmafast
opd
sigmaaldrich
absorb
od
nm
measur
plate
reader
biotek
quantit
human
igg
murin
challeng
studi
perform
use
black
maxisorp
plate
nalgen
nunc
coat
overnight
goat
antihuman
igg
h
l
pierc
plate
block
casein
blocker
thermo
serum
sampl
standard
curv
chrompur
human
igg
whole
molecul
jackson
lab
serial
dilut
plate
wash
stain
donkey
antihuman
igghrp
secondari
antibodi
jackson
visual
use
supersign
elisa
pico
reagent
thermo
luminesc
measur
use
perkin
elmer
envis
quantif
specif
influenza
b
human
igg
sera
mice
perform
describ
ha
protein
ha
yamagata
coat
reagent
flua
flub
purifi
protein
igg
use
standard
influenza
b
assay
respect
bind
elisa
recombin
ha
protein
express
purifi
previous
describ
elisa
plate
block
casein
thermo
scientif
serial
dilut
antibodi
incub
h
room
temperatur
bound
antibodi
detect
use
peroxidaseconjug
mous
antihuman
igg
antibodi
kpl
follow
develop
tmb
solut
kpl
absorb
measur
od
nm
mous
serum
reactiv
ha
preform
describ
except
secondari
antibodi
peroxidaseconjug
goat
antimous
igg
antibodi
dako
wildtyp
influenza
strain
obtain
center
diseas
control
prevent
purchas
american
tissu
cultur
collect
reassort
viru
produc
revers
genet
contain
ha
ahong
remain
seven
gene
segment
apuerto
ha
viru
also
contain
mutat
enhanc
murin
pathogenesi
virus
propag
embryon
chicken
egg
viru
titer
determin
mean
tissu
cultur
infect
dose
tcid
per
millilit
microneutr
assay
perform
previous
describ
briefli
tcid
viru
per
well
ad
threefold
serial
dilut
serum
purifi
flub
antibodi
dilut
serum
plate
complet
mem
medium
contain
ntosyllphenylalanyl
chloromethyl
keyton
trypsin
worthington
duplic
well
incub
co
madindarbi
canin
kidney
cell
per
well
ad
plate
plate
incub
co
approxim
h
na
activ
measur
ad
fluorescentlylabel
substrat
methylumbelliferylnacetyl
neuramin
acid
munana
sigma
well
h
viru
replic
repres
na
activ
quantifi
read
fluoresc
use
follow
set
excit
nm
emiss
nm
ten
flash
per
well
hai
assay
perform
serum
collect
day
post
infect
previous
describ
intramuscular
dna
electropor
thirti
minut
prior
dna
electropor
femal
balbc
nu
crl
mice
charl
river
pretreat
deliveri
site
intramuscular
im
inject
unit
hyaluronidas
enzym
sigmaaldrich
treatment
group
select
random
data
collect
blind
initi
studi
fig
either
flua
flub
dmab
plasmid
inject
im
tibiali
anterior
ta
andor
quadricep
q
muscl
mice
receiv
dna
one
site
ta
dna
two
site
right
ta
left
ta
dna
three
site
right
ta
left
ta
q
later
coadministr
studi
fig
mice
receiv
flua
flub
dmab
construct
modifi
flua
construct
design
express
heavychain
lightchain
peptid
separ
plasmid
gener
equival
serum
level
flua
igg
fewer
inject
site
oneplasmid
design
one
hundr
influenza
dna
antibodi
immunoprophylaxi
stc
elliott
et
al
wt
wt
mixtur
flua
heavychain
lightchain
plasmid
deliv
two
site
right
ta
right
q
plasmid
flub
deliv
two
site
left
ta
left
q
imep
perform
immedi
dna
inject
adapt
constant
current
devic
inovio
pharmaceut
lethal
influenza
challeng
sixto
eightweekold
balbc
mice
harlan
laboratori
receiv
flua
dmab
flub
dmab
irrelev
control
dmab
previous
describ
via
imep
day
prior
infect
one
day
prior
infect
protein
igg
monoclon
antibodi
amino
acid
sequenc
ident
encod
plasmid
dmab
administ
separ
group
mice
ip
dose
rang
mgkg
control
mice
receiv
nonspecif
protein
igg
ip
mice
receiv
intranas
infect
ld
tcid
mous
ld
tcid
mous
ld
b
victoria
tcid
mous
ld
b
yamagata
tcid
mous
mice
monitor
daili
weight
loss
surviv
day
percent
chang
weight
calcul
base
preinfect
weight
anim
lost
total
weight
euthan
weight
loss
record
limit
remaind
studi
blood
collect
day
infect
assess
amount
human
igg
serum
assess
viral
load
lung
addit
mice
euthan
day
post
infect
homolog
reinfect
studi
blood
sampl
taken
surviv
mice
day
initi
infect
confirm
clearanc
absenc
human
igg
data
shown
twentyeight
day
initi
infect
previouslyinfect
surviv
mice
rechalleng
viru
strain
lethal
dose
ident
initi
infect
alongsid
agematch
control
anim
hous
experiment
approv
conduct
accord
guidelin
set
nation
institut
health
anim
care
use
review
offic
us
armi
medic
depart
univers
pennsylvania
perelman
school
medicin
institut
anim
care
use
committe
medimmun
institut
anim
care
use
committe
murin
challeng
studi
conduct
accord
subsequ
perform
associ
assess
accredit
laboratori
anim
carecertifi
facil
standard
curv
graph
prepar
use
graphpad
prism
ec
ic
valu
calcul
use
nonlinear
regress
log
reciproc
serum
dilut
vs
respons
surviv
data
express
use
kaplanmei
surviv
curv
pvalu
calcul
logrank
mantelcox
test
data
support
find
studi
avail
correspond
author
upon
reason
request
